Formycon AG logo

FYB - Formycon AG Share Price

€25.5 0.1  0.4%

Last Trade - 14/08/20

Sector
Healthcare
Size
Small Cap
Market Cap £229.7m
Enterprise Value £209.5m
Revenue £30.7m
Position in Universe 560th / 1031
Bullish
Bearish
Unlock FYB Revenue
Momentum
Relative Strength (%)
1m -4.11%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -29.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
12.7 17.2 19.7 29.1 43.2 33.9 39.4 35.7 +21.8%
-30.9
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2019, Formycon AG revenues decreased 21% to EUR33.9M. Net loss totaled EUR2.3M vs. income of EUR7.1M. Revenues reflect Sales revenue decrease of 23% to EUR33.2M, Foreign Exchange Gain decrease of 17% to EUR59K. Net loss reflects Other Operating Expenses - rest increase of 36% to EUR3.9M (expense), Wages and Salaries increase of 15% to EUR7.8M (expense), Other increase of 13% to EUR1.2M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

FYB Revenue Unlock FYB Revenue

Net Income

FYB Net Income Unlock FYB Revenue

Normalised EPS

FYB Normalised EPS Unlock FYB Revenue

PE Ratio Range

FYB PE Ratio Range Unlock FYB Revenue

Dividend Yield Range

FYB Dividend Yield Range Unlock FYB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
FYB EPS Forecasts Unlock FYB Revenue
Profile Summary

Formycon AG is a Germany-based company engaged in providing biosimilar drugs and formulations. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The Company focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Public Since December 20, 2010
No. of Shareholders: n/a
No. of Employees: 113
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange XETRA
Shares in Issue 10,000,000
Free Float (0.0%)
Eligible for
ISAs
SIPPs
82152
View larger map
+
Address Fraunhoferstrasse 15, MARTINSRIED, 82152, Germany
Web http://www.formycon.com/
Phone +49 89 864667100
Contact ()
Auditors PanTaxAudit GmbH Wirtschaftsprufungsgesellschaft
FYB Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for FYB
Upcoming Events for FYB
Thursday 10th December, 2020
Formycon AG Annual Shareholders Meeting
Frequently Asked Questions for Formycon AG
What is the Formycon AG share price?

As of 14/08/20, shares in Formycon AG are trading at €25.5, giving the company a market capitalisation of £229.7m. This share price information is delayed by 15 minutes.

How has the Formycon AG share price performed this year?

Shares in Formycon AG are currently trading at €25.5 and the price has moved by -12.71% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Formycon AG price has moved by -13.11% over the past year.

What are the analyst and broker recommendations for Formycon AG?

Of the analysts with advisory recommendations for Formycon AG, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Formycon AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Formycon AG next release its financial results?

Formycon AG is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the Formycon AG dividend yield?

Formycon AG does not currently pay a dividend.

Does Formycon AG pay a dividend?

Formycon AG does not currently pay a dividend.

When does Formycon AG next pay dividends?

Formycon AG does not currently pay a dividend.

How do I buy Formycon AG shares?

To buy shares in Formycon AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Formycon AG?

Shares in Formycon AG are currently trading at €25.5, giving the company a market capitalisation of £229.7m.

Where are Formycon AG shares listed? Where are Formycon AG shares listed?

Here are the trading details for Formycon AG:

Country of listing: Germany
Exchange: GER
Ticker Symbol: FYB
What kind of share is Formycon AG?

Based on an overall assessment of its quality, value and momentum, Formycon AG is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Formycon AG share price forecast 2020?

Shares in Formycon AG are currently priced at €25.5. At that level they are trading at 33.15% discount to the analyst consensus target price of 0.00.

Analysts covering Formycon AG currently have a consensus Earnings Per Share (EPS) forecast of -0.233 for the next financial year.

How can I tell whether the Formycon AG share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Formycon AG. Over the past six months, the relative strength of its shares against the market has been 7.63%. At the current price of €25.5, shares in Formycon AG are trading at -3.55% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Formycon AG PE Ratio?

We were not able to find PE ratio data for Formycon AG.

Who are the key directors of Formycon AG?

Formycon AG's management team is headed by:

Nicolas Combe - CFO
Olaf Stiller - CSU
Peter Wendeln - SUB
Carsten Brockmeyer - CEO
Hermann Vogt - VSU
Stefan Glombitza - COO
Who are the major shareholders of Formycon AG?

Here are the top five shareholders of Formycon AG based on the size of their shareholding:

Family Office Wendeln Individual Investor
Percentage owned: 23.91% (2.39m shares)
DSP Beteiligungsgesellschaft GmbH & Co. KG Corporation
Percentage owned: 8.9% (890k shares)
Stiller (Olaf) Individual Investor
Percentage owned: 3.89% (389k shares)
Combe (Nicoals) Individual Investor
Percentage owned: 3.5% (350k shares)
Brockmeyer (Carsten) Individual Investor
Percentage owned: 3.07% (307k shares)
Similar to FYB
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.